337 related articles for article (PubMed ID: 28318769)
1. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil.
Andrade AL; Minamisava R; Tomich LM; Lemos AP; Gorla MC; de Cunto Brandileone MC; Domingues CMS; de Moraes C; Policena G; Bierrenbach AL;
Vaccine; 2017 Apr; 35(16):2025-2033. PubMed ID: 28318769
[TBL] [Abstract][Full Text] [Related]
2. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
[TBL] [Abstract][Full Text] [Related]
3. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
[TBL] [Abstract][Full Text] [Related]
4. Long-term impacts of MenC vaccination campaign in the Salvador, Brazil metropolitan region: A comparison of pre- and post-vaccine periods.
Monalisa Mendes Dantas Sales N; Azevedo J; Teles Bastos Ribeiro M; Fonseca de Freitas H; Pedreira da Silva Filho H; Machado Cordeiro S; Galvão Reis M; Neves Reis J
Vaccine; 2020 Sep; 38(40):6267-6273. PubMed ID: 32741673
[TBL] [Abstract][Full Text] [Related]
5. Impact of vaccination during an epidemic of serogroup C meningococcal disease in Salvador, Brazil.
Cardoso CW; Pinto LL; Reis MG; Flannery B; Reis JN
Vaccine; 2012 Aug; 30(37):5541-6. PubMed ID: 22749604
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of meningococcal serogroup C vaccine programmes.
Borrow R; Abad R; Trotter C; van der Klis FR; Vazquez JA
Vaccine; 2013 Sep; 31(41):4477-86. PubMed ID: 23933336
[TBL] [Abstract][Full Text] [Related]
7. Serogroup C
Findlow H; Campbell H; Lucidarme J; Andrews N; Linley E; Ladhani S; Borrow R
Euro Surveill; 2019 Jan; 24(1):. PubMed ID: 30621818
[TBL] [Abstract][Full Text] [Related]
8. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.
de Voer RM; Mollema L; Schepp RM; de Greeff SC; van Gageldonk PG; de Melker HE; Sanders EA; Berbers GA; van der Klis FR
PLoS One; 2010 Aug; 5(8):e12144. PubMed ID: 20730091
[TBL] [Abstract][Full Text] [Related]
9. [Mass vaccination campaign against serogroup C meningococcal disease, municipality of Itapeva, Sao Paulo].
Centro de Vigilância Epidemiológica Prof. Alexandre Vranjac, Secretaria de Estado da Saúde de São Paulo
Rev Saude Publica; 2005 Feb; 39(1):139-40. PubMed ID: 15654472
[No Abstract] [Full Text] [Related]
10. Evaluation of the impact of serogroup C meningococcal disease vaccination program in Brazil and its regions: a population-based study, 2001-2013.
Moraes C; Moraes JC; Silva GD; Duarte EC
Mem Inst Oswaldo Cruz; 2017 Apr; 112(4):237-246. PubMed ID: 28327788
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of meningococcal C conjugate vaccine in Salvador, Brazil: a case-control study.
Cardoso CW; Ribeiro GS; Reis MG; Flannery B; Reis JN
PLoS One; 2015; 10(4):e0123734. PubMed ID: 25874777
[TBL] [Abstract][Full Text] [Related]
12. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
13. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
Stoof SP; van der Klis FR; van Rooijen DM; Bogaert D; Trzciński K; Sanders EA; Berbers GA
Vaccine; 2015 Jul; 33(32):3933-9. PubMed ID: 26100925
[TBL] [Abstract][Full Text] [Related]
14. Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.
Kaaijk P; van der Ende A; Berbers G; van den Dobbelsteen GP; Rots NY
BMC Infect Dis; 2012 Feb; 12():35. PubMed ID: 22316426
[TBL] [Abstract][Full Text] [Related]
15. Meningococcal disease epidemiology in Brazil (2005-2018) and impact of MenC vaccination.
Aparecido Nunes A; De Jesus Lopes De Abreu A; Cintra O; A C T Cintra M; Barbosa Coelho E; Nogueira Castro De Barros E
Vaccine; 2021 Jan; 39(3):605-616. PubMed ID: 33358262
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination.
Archer BN; Chiu CK; Jayasinghe SH; Richmond PC; McVernon J; Lahra MM; Andrews RM; McIntyre PB;
Med J Aust; 2017 Nov; 207(9):382-387. PubMed ID: 29092704
[TBL] [Abstract][Full Text] [Related]
17. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination.
Bijlsma MW; Brouwer MC; Spanjaard L; van de Beek D; van der Ende A
Clin Infect Dis; 2014 Nov; 59(9):1216-21. PubMed ID: 25069869
[TBL] [Abstract][Full Text] [Related]
18. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
[TBL] [Abstract][Full Text] [Related]
19. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
[TBL] [Abstract][Full Text] [Related]
20. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
